sur Moderna, Inc. (NASDAQ:MRNA)
Moderna to Present mRNA Therapeutics Data at 2025 ICIEM
Moderna, Inc. (NASDAQ:MRNA) has announced the acceptance of five abstracts on its investigational mRNA therapeutics for presentation at the 2025 International Congress of Inborn Errors of Metabolism, to be held in Kyoto, Japan. Covering programs including propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a), this marks the first time Moderna shares data at a scientific congress for MMA and GSD1a.
Oral presentations will explore topics such as the clinical burden of propionic acidemia in Japan and mRNA-3705 therapy for MMA. Additionally, interim and final results of studies on mRNA-3927 for treating PA will be unveiled. Poster presentations will highlight model-informed dose selection for mRNA-3705 and interim data from mRNA-3745 therapy for GSD1a.
The presentations aim to deliver crucial insights into Moderna’s advancements in mRNA therapeutics, building on its established role in the field of mRNA medicine.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Moderna, Inc.